ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

NCT01921335 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Brain Metastases From HER2 and Breast Cancer
Advanced HER2-positive Breast Cancer

Interventions

DRUG: ARRY-380 Twice Daily Dosage
DRUG: ARRY-380 Once Daily
DRUG: Trastuzumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]